<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709081</url>
  </required_header>
  <id_info>
    <org_study_id>ACH228-003</org_study_id>
    <secondary_id>CA28776</secondary_id>
    <nct_id>NCT04709081</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of ACH-0145228</brief_title>
  <official_title>A Two-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0145228 and Midazolam, Digoxin, and Itraconazole in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 2-part study (Part 1 and Part 2), with each part being an open-label, fixed&#xD;
      sequence, 2-period study in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2019</start_date>
  <completion_date type="Actual">April 16, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 and Part 2 could be conducted concurrently or separately.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUC0-inf Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cmax Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Tmax Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole</measure>
    <time_frame>Up to 96 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) After Multiple Doses Of ACH-0145228 Coadministered With A Single Dose Of Midazolam</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number Of Participants With TEAEs After Multiple Doses Of ACH-0145228 Coadministered With A Single Dose Of Digoxin</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number Of Participants With TEAEs After A Single Dose Of ACH-0145228 Coadministered With Multiple Doses Of Itraconazole</measure>
    <time_frame>Day 1 (postdose) through follow-up (14 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: ACH-0145228, Midazolam, and Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received single doses of midazolam and digoxin.&#xD;
Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.&#xD;
Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ACH-0145228 and Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of ACH-0145228.&#xD;
Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.&#xD;
Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0145228</intervention_name>
    <description>ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.</description>
    <arm_group_label>Part 1: ACH-0145228, Midazolam, and Digoxin</arm_group_label>
    <arm_group_label>Part 2: ACH-0145228 and Itraconazole</arm_group_label>
    <other_name>ALXN2050</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam was dosed at 2 mg (1 milliliter [mL] of a 2 mg/mL syrup).</description>
    <arm_group_label>Part 1: ACH-0145228, Midazolam, and Digoxin</arm_group_label>
    <other_name>Midazolam HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.</description>
    <arm_group_label>Part 1: ACH-0145228, Midazolam, and Digoxin</arm_group_label>
    <other_name>Lanoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).</description>
    <arm_group_label>Part 2: ACH-0145228 and Itraconazole</arm_group_label>
    <other_name>Sporanox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at screening.&#xD;
&#xD;
          2. No clinically significant history or presence of electrocardiogram abnormalities at&#xD;
             screening and prior to first dosing in Period 1.&#xD;
&#xD;
          3. Non-sterile male participants must agree to abstinence or use a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
          4. Female participants must be of non-childbearing potential and need not employ a method&#xD;
             of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities.&#xD;
&#xD;
          2. History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          3. History or presence of drug or alcohol abuse within previous 2 years, current&#xD;
             tobacco/nicotine user, or positive for alcohol and/or drug screen at screening or Day&#xD;
             -1 of Period 1.&#xD;
&#xD;
          4. History or presence of clinically significant seizures, head injury, or head trauma.&#xD;
&#xD;
          5. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          6. A history of significant multiple and/or severe allergies or has had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          7. Body temperature ≥ 38.0°Celsius at screening or prior to first dosing in Period 1.&#xD;
&#xD;
          8. Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days&#xD;
             before first dosing, or receipt of blood products within 6 months prior to first&#xD;
             dosing.&#xD;
&#xD;
          9. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever is longer.&#xD;
&#xD;
         10. History or presence of any risk factors for Torsades de Pointes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Complement</keyword>
  <keyword>Capsule</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Drug Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

